FIELD: chemistry of nucleic acids, medicine, pharmacy. SUBSTANCE: invention relates to oligonucleotides and their derivatives that can be used for inhibition of expression of isoprenylprotein transferases. Oligonucleotides have a formula (I): P-O-R (I) where P is absent or means a sequence of a single or more bases taken from A (adenine), T (thymine), C (cytosine) or G (guanine); O is a sequence taken from: SEQ IDN 1: AGAAGCCATG AT; SEQ IDN 2: GGACGTGACT GT; SEQ IDN 3: AAGGAGTAGC AG; SEQ IDN 4: CAGGCAGTAG CA; SEQ IDN 5: CCCGTCGTCC AT; SEQ IDN 6: CTGTCCCTGT AC; SEQ IDN 7: ACTTCTCTCT CC; SEQ IDN 8: ACTTGGTCCT AA; SEQ IDN 9: GCCATCATTC TG; SEQ IDN 10: GATCTGGA AC; SEQ IDN 11; CTCAATAGCA TC; SEQ IDN 12: GTTTTTGGGC TG; SEQ IDN 13: TCTCACATCC TC; SEQ IDN 14: TTGTAAGAAC TG; SEQ IDN 15: GAAGTGCTTC TC; SEQ IDN 16: GCCTCTTTC AG; SEQ IDN 17: GGCATCTGTC AG; SEQ IDN 18: CGGCTGGCAT CC; SEQ IDN 19: GAACTGACAC AC; SEQ IDN 20: ACGATCACAT CA; SEQ IDN 21: ATCAACATGC AG; SEQ IDN 22: CTGCATATTCG AC; SEQ IDN 23: CAGTGCACCA GC; SEQ IDN 24: CTGCAGCCTC GG; SEQ IDN 25: ACTCTGGA CC; SEQ IDN 26: CAAGAATCCT CG; SEQ IDN 27: ACATCTGCTC TG; SEQ IDN 28: TCTGTACTCG TC; SEQ IDN 29: CTACAGTACA GC; SEQ IDN 30: CCCGTCGTCC ATAGG; SEQ IDN 31: CCCGTCGTCC ATAGGGGA; SEQ IDN 32: CCCGTCGTCC ATAGGGGAC GC; SEQ IDN 33: GGACGTGACT GTTTC; SEQ IDN 34: GGACGTGACT GTTTCCAC; SEQ IDN 35: GGACGTGACT GTTTCCAACTG; SEQ IDN 36: GGACGTGACT GTTTCCACTG AGTC. R is absent or means a sequence of a single or more bases taken from A, T, C or G. Pharmaceutical composition showing antiproliferative effect has at least one oligonucleotide of the formula (I) as an active component in mixture with pharmaceutically acceptable vehicle and/or carrier that is able for administration route. Proposed composition can be used for treatment or prophylaxis of diseases in human and animals caused by abnormal and/or nonregulated proliferation. EFFECT: enhanced effectiveness of oligonucleotides. 14 cl, 9 tbl
